KGKathryn A. Gibson

Kathryn A. Gibson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathryn A. Gibson has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characteristics, Disease Burden and Healthcare Resource Use of Moderate and Severe Atopic Dermatitis in Australia

    by John C. Su, Anita Townsend, Kathryn A. Gibson, Laura Kauffman, Sam Colman, Rachel S. Newson

    Background/Objectives: Atopic dermatitis (AD) affects up to 2.8 million Australians. This study examines the current characteristics of the disease and the burden placed on Australian adults living with moderate‐to‐severe AD. Method: A cross‐sectional online survey of persons with moderate to severe AD ( n = 300), enrolled in October 2024, was conducted, examining self‐reported demographics, AD characteristics and burden of disease, including the Patient Oriented Eczema Measure (POEM) and the Dermatology Life Quality Index (DLQI). All analyses were descriptive and assessed by the following subgroups: moderate AD, severe AD and severe AD on advanced therapy. Result: The mean (SD) age of participants was 38.2 (11.87) years, with 53.7% being female and 69.7% Caucasian. AD was active in 92.3% of participants, with a mean of 56.9 (65.9) active flare days in the past 6 months. The mean POEM score was 14.6 (5.90), and 90.7% reported disturbed sleep due to AD. Among employed respondents, the mean number of reduced workdays due to AD in the previous month was 3.2 (3.22). AD significantly impacted 59.0% of respondents' ability to engage in activities of interest. Co‐morbidities were common, with 48.3% having at least one; the most prevalent being allergies (29.0%), anxiety (24.0%), and depression (13.7%). Conclusion: Nearly all participants experienced sleep disturbances, and the prevalence of anxiety and depression was high. Active flares in AD were frequent. Work and social impairment in moderate‐to‐severe AD was significant, including for many receiving currently available advanced therapies. There remains a need for new treatments in Australia to alleviate the current AD burden.


  • Open Access

    Should Joint Deformity, which is More Common Than Swelling or Tenderness, be Assessed in all Rheumatoid Arthritis Patients and Databases?

    by Theodore Pincus, Tengfei Li, Kathryn A. Gibson

    Objective: We analyzed 28 joint counts in 173 contemporary routine care patients with rheumatoid arthritis (RA), who had disease duration of 10 years and were examined in 2021, for swollen joint count (SJC), tender joint count (TJC)/pain on motion, and deformity joint count (DJC)/limited motion. In addition, we computed DJC according to Disease Activity Score in 28 joints (DA28), Clinical Disease Activity Index (CDAI), and Routine Assessment of Patient Index Data 3 (RAPID3) as remission/low or moderate/high activity or severity.Methods: This report presents a retrospective analyses of a cross‐sectional Australian database for medians and prevalences of SJC, TJC, and DJC, including in RA index categories.Results: Median values were 0 for SJC, 2.0 for TJC, and 4.0 for DJC, respectively, including SJC of 0,1 in 123 patients (71%), TJC of 0,1 in 82 patients (47%), SJC+TJC of 0,1 in 73 patients (42%), and DJC of 0,1 in 65 patients (38%). Among 4,498 joints, 1,330 with any abnormality included 286 swollen joints (6%), 590 tender joints (13%), 879 deformed joints (20%), 37 only swollen joints (1%), 289 only tender joints (6%), 659 only deformed joints (15%), 458 joints with two abnormalities (10%), and 80 joints with three abnormalities (2%). The 73 of all 173 with patients with SJC and TJC 0,1 (42%), included 56% to 67% who were classified in remission or low DAS28 ESR erythrocyte sedimentation rate, CDAI, or RAPID3 activity or severity, of whom 47% to 58% had DJC ≥2, whereas 11% to 36% were classified as moderate or high RA index activity or severity, of whom 57% to 58% had DJC ≥2.Conclusion: SJC+TJC of 0,1 was more common than a DJC of 0,1 in contemporary patients with RA. DJC was ≥2 in the majority of patients who met SJC+TJC remission criteria for RA indices, as in patients who were classified as moderate/high although they met SJC+TJC remission criteria. DJC should be included in long‐term routine care and RA databases.


  • Open Access

    Elevated DAS28, CDAI, RAPID3 and five of seven RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQ

    by Theodore Pincus, Tengfei Li, Kathryn A Gibson

    Objective: To analyze three MDHAQ (Multidimensional Health Assessment Questionnaire) patient distress screening indices, MAS2 (MDHAQ anxiety screen), MDS2 (MDHAQ depression screen) and FAST3F (fibromyalgia assessment screening tool), for potential associations with elevated rheumatoid arthritis (RA) activity/severity indices in routine care patients. Methods: A cross-sectional database included the seven RA core data set measures and three MDHAQ patient distress indices. Mean individual measures and five indices—DAS28-ESR (disease activity score 28-erythrocyte sedimentation rate), DAS28–CRP (DAS28–C-reactive protein), SDAI (simplified disease activity index), CDAI (clinical disease activity index), and RAPID3 (routine assessment of patient index data),—and the number of patients classified into high, moderate, low or remission, were computed according to positive or negative MDHAQ screening indices, including in patients with 0,1 vs ≥2 swollen joints, analyzed using t tests and chi2 tests. Results: Among 173 patients, positive screening was seen in 37% for MAS2, 27% for MDS2, 31% for FAST3F and 45% for at least one of these three MDHAQ screening indices. All five RA indices and five of seven core data set measures were elevated significantly (P-value < 0.01), other than swollen joint count (SJC), ESR and CRP, in MAS2, MDS2 and/or FAST3F positive patients, generally to a higher activity/severity category. In the 27–41% of all patients with 0 or 1 SJC but moderate/high RA index activity/severity, a positive MDHAQ anxiety, depression and/or fibromyalgia screen was seen in 54–100%. Conclusion: Five RA indices and five of seven individual core data set measures are elevated significantly in patients who screen positive for anxiety, depression and/or fibromyalgia on MDHAQ indices.


  • Open Access

    Safer medicines To reduce falls and refractures for OsteoPorosis (#STOP): a study protocol for a randomised controlled trial of medical specialist-initiated pharmacist-led medication management reviews in primary care

    by Rebekah Jane Moles, Lin Perry, Justine M Naylor, Jacqueline Center, Peter Ebeling, Gustavo Duque, Gabor Major, Christopher White, Christopher Yates, Matthew Jennings, et al.

    Introduction Minimal trauma fractures (MTFs) often occur in older patients with osteoporosis and may be precipitated by falls risk-increasing drugs. One category of falls risk-increasing drugs of concern are those with sedative/anticholinergic properties. Collaborative medication management services such as Australia’s Home Medicine Review (HMR) can reduce patients’ intake of sedative/anticholinergics and improve continuity of care. This paper describes a protocol for an randomised controlled trial to determine the efficacy of an HMR service for patients who have sustained MTF. Method and analysis Eligible participants are as follows: ≥65 years of age, using ≥5 medicines including at least one falls risk-increasing drug, who have sustained an MTF and under treatment in one of eight Osteoporosis Refracture Prevention clinics in Australia. Consenting participants will be randomised to control (standard care) or intervention groups. For the intervention group, medical specialists will refer to a pharmacist for HMR focused on reducing falls risk predominately through making recommendations to reduce falls risk medicines, and adherence to antiosteoporosis medicines. Twelve months from treatment allocation, comparisons between groups will be made. The main outcome measure is participants’ cumulative exposure to sedative and anticholinergics, using the Drug Burden Index. Secondary outcomes include medication adherence, emergency department visits, hospitalisations, falls and mortality. Economic evaluation will compare the intervention strategy with standard care. Ethics and dissemination Approval was obtained via the New South Wales Research Ethics and Governance Information System (approval number: 2021/ETH12003) with site-specific approvals granted through Human Research Ethics Committees for each research site. Study outcomes will be published in peer-reviewed journals. It will provide robust insight into effectiveness of a pharmacist-based intervention on medicine-related falls risk for patients with osteoporosis. We anticipate that this study will take 2 years to fully accrue including follow-up. Trial registration number ACTRN12622000261718.


  • Open Access

    RheuMetric Quantitative 0 to 10 Physician Estimates of Inflammation, Damage, and Distress in Rheumatoid Arthritis: Validation Against Reference Measures

    by Nicholas Rodwell, Geraldine Hassett, Paul Bird, Theodore Pincus, Joseph Descallar, Kathryn A. Gibson

    Objective: To analyze a RheuMetric checklist, which includes four feasible physician 0 to 10 scores for DOCGL, inflammation (DOCINF), damage (DOCDAM), and distress (DOCSTR) for criterion and discriminant validity against standard reference measures.Methods: A prospective, cross‐sectional assessment was performed at one routine care visit at Liverpool Hospital, Sydney, Australia. Rheumatologists recorded DOCGL, DOCINF, DOCDAM, DOCSTR, and 28 joint counts for swelling (SJC), tenderness (TJC), and limited motion/deformity (DJC). Patients completed a multidimensional health assessment questionnaire (MDHAQ), which includes routine assessment of patient index data (RAPID3), fibromyalgia assessment screening tool (FAST4), and MDHAQ depression screen (MDS2). Laboratory tests and radiographic scores were recorded. RheuMetric estimates of inflammation, damage, and distress were compared with reference and other measures using correlations and linear regressions.Results: In 173 patients with RA, variation in RheuMetric DOCINF was explained significantly by SJC and inversely by disease duration; variation in DOCDAM was explained significantly by DJC, radiographic scores, and physical function; and variation in DOCSTR was explained significantly by fibromyalgia and depression.Conclusion: RheuMetric DOCINF, DOCDAM, and DOCSTR estimates were correlated significantly and specifically with reference measures of inflammation, damage, and distress, documenting criterion and discriminant validity.


  • Open Access

    Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study

    by Kathryn Connelly, Rangi Kandane‐Rathnayake, Alberta Hoi, Worawit Louthrenoo, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Jiacai Cho, Aisha Lateef, Cs Lau, et al.

    Objective: In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long‐term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years of follow‐up.Methods: We used data from a large multicenter, longitudinal SLE cohort in which patients received standard of care. The first visit with active disease (defined as SLE Disease Activity Index 2000 [SLEDAI‐2K] score ≥6) was designated as baseline, and mSRI attainment (defined as a reduction in SLEDAI‐2K ≥4 points with no worsening in physician global assessment ≥0.3 points) was determined at annual intervals from baseline up to 5 years. Associations between mSRI attainment and outcomes including disease activity, glucocorticoid dose, flare, damage accrual, Lupus Low Disease Activity State (LLDAS), and remission were studied.Results: We included 2,060 patients, with a median baseline SLEDAI‐2K score of 8. An mSRI response was attained by 56% of patients at 1 year, with similar responder rates seen at subsequent annual time points. Compared to nonresponders, mSRI responders had significantly lower disease activity and prednisolone dose and higher proportions of LLDAS and remission attainment at each year, and less damage accrual at years 2 and 3. Furthermore, mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes, including damage accrual (odds ratio [OR] range 0.58–0.69, P < 0.05 for damage accrual ORs at all time points).Conclusion: In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long‐term follow‐up, supporting the clinical meaningfulness of SRI attainment as an SLE trial end point.


  • Open Access

    Correlation of patient‐reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis

    by Louise Ward, Michael Oliffe, Barry Kane, Diana Chessman, Donna Meaney, Fiona Briggs, Kathryn Gibson, Les Barnsley, Daniel Sumpton

    Aim: A treat‐to‐target strategy is recommended for management of psoriatic arthritis (PsA), although there is lack of agreement regarding the best measure of disease activity to target. Physician assessments included in traditional indices can be complex and time consuming to complete and cannot be readily conducted by telehealth. This study compares the routine assessment of patient index data 3 (RAPID3), an efficient tool comprising patient self‐assessment, with traditional clinician‐led composite measures in the PsA clinic setting.Methods: Data were collected prospectively from July 2016 to March 2020 in 2 dedicated PsA clinics in Sydney, Australia. A receiver operating characteristic (ROC) curve was created for comparison of RAPID3 score with composite scores minimal disease activity (MDA), very low disease activity (VLDA) and disease activity in psoriatic arthritis (DAPSA) in low disease activity or remission.Results: Ninety‐three patients had simultaneous collection of RAPID3 and MDA measures. Mean (SD) age was 49.9 (13.5) years, 50.5% were male and 23 (24.7%) had erosive disease at baseline. RAPID3 scores ≤3.2 and ≤2.7 (range 0‐30) had high sensitivity and specificity for VLDA and DAPSA remission respectively, with ROC curve area under the curve (95% CI) of 0.94 (0.91‐0.97) and 0.96 (0.93‐0.99).Conclusion: RAPID3 has good agreement with physician‐led composite scores of MDA, VLDA and DAPSA, and provides a viable alternative to composite scores. This is particularly helpful in settings that do not allow for clinical examination, for example telehealth.


  • Open Access

    ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

    by Rangi Kandane-Rathnayake, Worawit Louthrenoo, Alberta Hoi, Shue-Fen Luo, Yeong-Jian J. Wu, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Sandra V. Navarra, et al.

    Background: The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerated the prevalence of these states and examined their association with adverse outcomes. Methods: Data were collected prospectively in a 13-country longitudinal SLE cohort between 2013 and 2019. Unmet need was defined as never attaining lupus low disease activity state (LLDAS), a time-adjusted mean SLEDAI-2K (AMS) > 4, or ever experiencing high disease activity status (HDAS; SLEDAI-2K ≥10). Health-related quality of life (HRQoL) was assessed using SF36 (v2) and damage accrual using the SLICC-ACR SLE Damage Index (SDI). Results: A total of 3384 SLE patients were followed over 30,313 visits (median [IQR] follow-up 2.4 [0.4, 4.3] years). Eight hundred thirteen patients (24%) never achieved LLDAS. Median AMS was 3.0 [1.4, 4.9]; 34% of patients had AMS > 4. Twenty-five per cent of patients had episodes of HDAS. Each of LLDAS-never, AMS>4, and HDAS-ever was strongly associated with damage accrual, higher glucocorticoid use, and worse HRQoL. Mortality was significantly increased in LLDAS-never (adjusted HR [95% CI] = 4.98 [2.07, 12.0], pCI] = 5.45 [2.75, 10.8], p<0.001) patients. Conclusion: Failure to achieve LLDAS, high average disease activity, and episodes of HDAS were prevalent in SLE and were significantly associated with poor outcomes including organ damage, glucocorticoid exposure, poor quality of life, and mortality.


  • Open Access

    Computer-Based Decision Tools for Shared Therapeutic Decision-making in Oncology: Systematic Review

    by Alan Yung, Judy Kay, Philip Beale, Kathryn A Gibson, Tim Shaw

    Background: Therapeutic decision-making in oncology is a complex process because physicians must consider many forms of medical data and protocols. Another challenge for physicians is to clearly communicate their decision-making process to patients to ensure informed consent. Computer-based decision tools have the potential to play a valuable role in supporting this process. Objective: This systematic review aims to investigate the extent to which computer-based decision tools have been successfully adopted in oncology consultations to improve patient-physician joint therapeutic decision-making. Methods: This review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 checklist and guidelines. A literature search was conducted on February 4, 2021, across the Cochrane Database of Systematic Reviews (from 2005 to January 28, 2021), the Cochrane Central Register of Controlled Trials (December 2020), MEDLINE (from 1946 to February 4, 2021), Embase (from 1947 to February 4, 2021), Web of Science (from 1900 to 2021), Scopus (from 1969 to 2021), and PubMed (from 1991 to 2021). We used a snowball approach to identify additional studies by searching the reference lists of the studies included for full-text review. Additional supplementary searches of relevant journals and gray literature websites were conducted. The reviewers screened the articles eligible for review for quality and inclusion before data extraction. Results: There are relatively few studies looking at the use of computer-based decision tools in oncology consultations. Of the 4431 unique articles obtained from the searches, only 10 (0.22%) satisfied the selection criteria. From the 10 selected studies, 8 computer-based decision tools were identified. Of the 10 studies, 6 (60%) were conducted in the United States. Communication and information-sharing were improved between physicians and patients. However, physicians did not change their habits to take advantage of computer-assisted decision-making tools or the information they provide. On average, the use of these computer-based decision tools added approximately 5 minutes to the total length of consultations. In addition, some physicians felt that the technology increased patients’ anxiety. Conclusions: Of the 10 selected studies, 6 (60%) demonstrated positive outcomes, 1 (10%) showed negative results, and 3 (30%) were neutral. Adoption of computer-based decision tools during oncology consultations continues to be low. This review shows that information-sharing and communication between physicians and patients can be improved with the assistance of technology. However, the lack of integration with electronic health records is a barrier. This review provides key requirements for enhancing the chance of success of future computer-based decision tools. However, it does not show the effects of health care policies, regulations, or business administration on physicians’ propensity to adopt the technology. Nevertheless, it is important that future research address the influence of these higher-level factors as well. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021226087; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021226087


  • Open Access

    A Self-Report Multidimensional Health Assessment Questionnaire (MDHAQ) for Face-To-Face or Telemedicine Encounters to Assess Clinical Severity (RAPID3) and Screen for Fibromyalgia (FAST) and Depression (DEP)

    by Kathryn A. Gibson, Theodore Pincus

    Purpose of Review: To update the clinical value of a patient self-report multidimensional health assessment questionnaire (MDHAQ). Recent Findings: The MDHAQ includes 10 individual quantitative scores for physical function, pain, patient global assessment, fatigue, sleep, anxiety, depression, morning stiffness, change in status, and exercise status, and 5 indices, RAPID3 (routine assessment of patient index data) to assess clinical status in all diseases studied, FAST3 (fibromyalgia assessment screening tool) and MDHAQ-Dep (depression) to screen for fibromyalgia and/or depression, RADAI self-report of specific painful joints and joint count, and a symptom checklist for review of systems, and recognition of flares and medication adverse events. The MDHAQ also uniquely queries traditional “medical” information concerning comorbidities, falls, trauma, new symptoms, illnesses, surgeries, hospitalizations, emergencies, medication changes, and medication side effects. Three MDHAQ versions include long for new patients, short for new and return patients, and telemedicine. An electronic MDHAQ (eMDHAQ) has been developed with software that can interface with any electronic medical record (EMR) through the HL7 FHIR standard. However, EMR collaboration and implementation have proven difficult. Summary: An MDHAQ provides a quantitative overview of patient status with far more information and documentation than an interview, involving minimal extra work for the physician.